The role of angiotensin-converting enzyme inhibitors (ACEI) in patients with cardiovascular risk;Papel de los inhibidores de la enzima conversora de la angiotensina en los pacientes con riesgo cardiovascular

Revista Clinica Espanola

Volumn 204, Issue 11, 2004, Pages 592-593

  Rodriguez Padial L ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PLACEBO; RAMIPRIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HYPERTENSION; MORTALITY; NOTE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 9444284307     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13067370     Document Type: Note

References (20)

1. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-6.
2. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihipertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-8.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major otucomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
4. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-8.
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
6. Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, et al. Heart Outcomes Prevention Evaluation. Effect of long-term therapy with ramipril in high-risk women. J Am Coll Cardiol 2002;40:693-702.
7. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE. Lancet 2000; 355:253-9.
8. Heinig RE. What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO HOPE. Diabetes Obes Metab 2002; (Suppl 1):S19-25.
9. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, et al. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001;286;1882-5.
10. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358:2130-1.
11. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001;38(6):E28-32.
12. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-8.
13. Lonn E. Angiotensin-coverting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr Atheroscler Rep 2002;4(5):363-72.
14. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tumchak W, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the simvastatin/enalapril coronary atherosclerosis trial (SCAT). Circulation 2000;102:1748-54.
15. Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotic ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-25.
16. Mancini GB, Henry GC, Macaya C, O'Neil BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996;94:258-65.
17. Witherow FN, Dawson P, Ludlam CA, Fox KA, Newby DE. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol 2002;40:961-6.
18. Klingbeil AU, Schneider M, Martus P, Messerly FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;155:41-6.
19. Mathew J, Sleight P, Lonn E, Hohnstone D, Pogue J, Yi Q, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615-21.
20. Malik IS, Bhatia VK, Kooner JS. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart 2001;85;539-43.